Karulkar, A., Jain, H., Kalra, D., Ravikumar, S., Vaibhaw, A., Shah, S., Firfiray, A., Pendhari, J., Siddarthan, N., Boyella, P. K., Shah, S., Melinkeri, S., Gupta, A., Mehta, P., Nair, C., Bhurani, D., Lahoti, A., Chakrapani, A., Padate, B., Shekhawat, P., Samal, P., Bajaj, R., Chandar, R., Lokireddy, P., Aribandi, A., Bagal, B., Badarkhe, G., P.K., J., Bajaj, K., KS, N., Dhakate, N., Kapoor, R., Bhargava, R., Tulpule, S., Damodar, S., Gupta, S., Chiraniya, S., Singh, S., Thirugnanam, R., Goli, V. B., Mathews, V., Kaul, E., Golamari, K. R., Subramanian, K., Nayak, L., Shetty, A., Murali, A., Jain, P., Bhattacharyya, R., Boya, R., Abhinav, R., Nair, V., Menon, H., Harimadhavan, M., Ansari, M. S., Tiwari, N., Darbar, S., Chawkekar, S., Sahay, S., Sundharam, M., Saroha, A., Basu, M., Jaiswal, A., Yadav, Y., Soni, S., Thorat, J., Purwar, S., Shah, N., Fry, T., Jain, N., Sengar, M., Purwar, R. (2025). Early use of talicabtagene autoleucel in r/r B-acute lymphoblastic leukemia is cost-effective: Improved efficacy, reduced toxicity and healthcare resource utilization support affordable access. Blood. https://doi.org/10.1182/blood-2025-1076